Therapeutic potential of LIF in multiple sclerosis

被引：35
|
作者：
Slaets, Helena [1 ,2 ]
Hendriks, Jerome J. A. [1 ,2 ]
Stinissen, Piet [1 ,2 ]
Kilpatrick, Trevor J. [3 ,4 ]
Hellings, Niels [1 ,2 ]
机构：
[1] Hasselt Univ, Biomed Res Inst, Diepenbeek, Belgium
[2] Transnat Univ Limburg, Sch Life Sci, Diepenbeek, Belgium
[3] Univ Melbourne, Ctr Neurosci, Melbourne, Vic 3010, Australia
[4] Univ Melbourne, Howard Florey Inst, Melbourne, Vic 3010, Australia
来源：
TRENDS IN MOLECULAR MEDICINE | 2010年 / 16卷 / 11期
关键词：
LEUKEMIA INHIBITORY FACTOR; LIMITS AUTOIMMUNE DEMYELINATION; CILIARY NEUROTROPHIC FACTOR; SPINAL-CORD-INJURY; NEURODEGENERATIVE CONDITIONS; SYNOVIAL-FLUID; MOUSE MODEL; STEM-CELLS; PHASE-II; CYTOKINE;
D O I：
10.1016/j.molmed.2010.08.007
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Therapies for multiple sclerosis (MS) reduce the relapse rate but are unable to stop neurological decline. Here, we evaluate the potential of leukemia inhibitory factor (LIF) as a novel therapeutic in diseases with a neurodegenerative and inflammatory component, such as MS. LIF, which can be a proinflammatory cytokine, can also modulate the immune response in a beneficial way. Recent evidence demonstrates a crucial role of LIF in neuroprotection and axonal regeneration as well as the prevention of demyelination. Finally, LIF is an important survival factor for stem cells and neuronal precursors. Therefore, we propose that LIF is a potential therapeutic candidate for MS.
引用
收藏
页码：493 / 500
页数：8
相关论文
共 50 条
  • [31] Semaphorin 7A as a Potential Therapeutic Target for Multiple Sclerosis
    Gutierrez-Franco, Ana
    Eixarch, Herena
    Costa, Carme
    Gil, Vanessa
    Castillo, Mireia
    Calvo-Barreiro, Laura
    Montalban, Xavier
    Del Rio, Jose A.
    Espejo, Carmen
    MOLECULAR NEUROBIOLOGY, 2017, 54 (06) : 4820 - 4831
  • [32] Therapeutic Potential of Astrocyte Purinergic Signalling in Epilepsy and Multiple Sclerosis
    Nobili, Paola
    Shen, Weida
    Milicevic, Katarina
    Bogdanovic Pristov, Jelena
    Audinat, Etienne
    Nikolic, Ljiljana
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [33] Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis
    Darlington, Peter J.
    Boivin, Marie-Noelle
    Bar-Or, Amit
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2011, 11 (09) : 1295 - 1303
  • [34] Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis
    Mehta, Lahar R.
    Dworkin, Robert H.
    Schwid, Steven R.
    NATURE CLINICAL PRACTICE NEUROLOGY, 2009, 5 (02): : 82 - 92
  • [35] Role of Gut Microbiota in Multiple Sclerosis and Potential Therapeutic Implications
    Wang, Xu
    Liang, Zhen
    Wang, Shengnan
    Ma, Di
    Zhu, Mingqin
    Feng, Jiachun
    CURRENT NEUROPHARMACOLOGY, 2022, 20 (07) : 1413 - 1426
  • [36] Potential therapeutic advantages of guanosine over inosine in multiple sclerosis
    Hanson, Erik A.
    MEDICAL HYPOTHESES, 2009, 73 (04) : 627 - 628
  • [37] The Therapeutic Potential of the Ketogenic Diet in Treating Progressive Multiple Sclerosis
    Storoni, Mithu
    Plant, Gordon T.
    MULTIPLE SCLEROSIS INTERNATIONAL, 2015, 2015
  • [38] Potential therapeutic and diagnostic approaches of exosomes in multiple sclerosis pathophysiology
    Hasaniani, Nima
    Nouri, Sina
    Shirzad, Moein
    Rostami-Mansoor, Sahar
    LIFE SCIENCES, 2024, 347
  • [39] Is T-bet a Potential Therapeutic Target in Multiple Sclerosis?
    Racke, Michael K.
    Yang, Yuhong
    Lovett-Racke, Amy E.
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2014, 34 (08): : 623 - 632
  • [40] Evaluation of new thalidomide analogues with therapeutic potential for multiple sclerosis
    Karlik, Stephen
    Contino-Pepin, Christine
    Parat, Audry
    Pucci, Bernard
    JOURNAL OF NEUROIMMUNOLOGY, 2008, 203 (02) : 229 - 229
12345